Vol. 5 No. 11 (2025)
Reimbursement Recommendations

Talazoparib (Talzenna)

decorative image of the issue cover

Published November 18, 2025

Key Messages

  • Canada’s Drug Agency (CDA-AMC) recommends that Talzenna in combination with enzalutamide should be reimbursed by public drug plans for the first-line treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) if certain conditions are met.
  • Talzenna plus enzalutamide should only be covered to treat adult patients with mCRPC who have an HRR mutation, have not been treated with an androgen receptor pathway inhibitor (ARPIi) for earlier stages of prostate cancer, and have not received treatments for mCRPC or a poly(ADP-ribose) polymerase inhibitor (PARPIi) for mCRPC. Moreover, patients should be in relatively good health.
  • Talzenna plus enzalutamide should only be reimbursed if it is prescribed by a clinician with expertise in treating prostate cancer, and should not be reimbursed when used in combination with other anticancer drugs.